NEW YORK, Jan. 15, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depository Shares of Qudian Inc. ("Qudian") (NYSE:QD) (1) pursuant and/or traceable to the Company’s Initial Public Offering on or about October 17, 2017; and/or (2) between October 18, 2017 and November 20, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Zolotukhin v. Qudian Inc., et al. (Case No. 1:17-cv-09894) in the United States District Court for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra-sbm/qudian-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Registration Statement issued in connection with the IPO failed to disclose that: (1) Qudian engaged in unethical business and accounting practices; (2) Qudian failed to maintain adequate control to ensure the protection and safety of its users’ personal information; and (3) as a result, Qudian was exposing detailed user data to leakages and online resale.
On November 21, 2017, media outlets reported that data from more than a million student clients of Qudian was leaked and possibly sold online.
If you suffered a loss in Qudian you have until February 12, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Anta Sports Expands Global Footprint With Strategic Puma Stake
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



